Physician profile
Paul Jones
NPI 1376582684
$1,037.88
in general payments reported to CMS, 2019-2025
11 companies · $49.02 in 2025
The $49.02 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $146 · 2021: $145 · 2022: $392 · 2023: $91.39 · 2024: $88.77 · 2025: $49.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $229.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $391.95 | 2022 | |
| Amgen INC. | $187.74 | 2019-2025 | Repatha, Repatha, Otezla |
| Esperion Therapeutics, INC. | $142.49 | 2021-2024 | Nexletol |
| Pfizer INC. | $81.26 | 2019-2020 | |
| Glaxosmithkline, LLC. | $62.23 | 2020-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Arthrex, INC. | $45.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $29.02 | 2020-2023 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.00 | 2019 | |
| Lundbeck LLC | $25.82 | 2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $24.66 | 2025 | |
| Genentech USA, INC. | $21.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.